TY - JOUR
T1 - Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
AU - Solomon, Joshua
AU - Festa, Maria Carolina
AU - Chatzizisis, Yiannis S.
AU - Samanta, Ratna
AU - Suri, Rita S.
AU - Mavrakanas, Thomas A.
N1 - Funding Information:
Dr. Mavrakanas is supported from the Fonds de Recherche Santé Quebec (FRSQ) Junior 1 clinician scholar program (# 298742 ) and has received operating grants from the Quebec Society of Nephrology (# 309790 ) and the Department of Medicine at McGill University.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/2
Y1 - 2023/2
N2 - Diabetes drives an increasing burden of cardiovascular and renal disease worldwide, motivating the search for new hypoglycemic agents that confer cardiac and renal protective effects. Although initially developed as hypoglycemic agents, sodium-glucose co-transporter 2 (SGLT-2) inhibitors have since been studied in patients with and without diabetes for the management of heart failure and chronic kidney disease. A growing body of evidence supports the efficacy and safety of SGLT-2 inhibitors in patients with chronic kidney disease (CKD), based on complex mechanisms of action that extend far beyond glucosuria and that confer beneficial effects on cardiovascular and renal hemodynamics, fibrosis, inflammation, and end-organ protection. This review focuses on the pharmacology and pathophysiology of SGLT-2 inhibitors in patients with CKD, as well as their cardiovascular and renal effects in this population. We are focusing on the five agents that have been tested in cardiovascular outcome trials and that have been approved either in Europe or in North America: empagliflozin, dapagliflozin, canagliflozin, ertugliglozin, and sotagliflozin.
AB - Diabetes drives an increasing burden of cardiovascular and renal disease worldwide, motivating the search for new hypoglycemic agents that confer cardiac and renal protective effects. Although initially developed as hypoglycemic agents, sodium-glucose co-transporter 2 (SGLT-2) inhibitors have since been studied in patients with and without diabetes for the management of heart failure and chronic kidney disease. A growing body of evidence supports the efficacy and safety of SGLT-2 inhibitors in patients with chronic kidney disease (CKD), based on complex mechanisms of action that extend far beyond glucosuria and that confer beneficial effects on cardiovascular and renal hemodynamics, fibrosis, inflammation, and end-organ protection. This review focuses on the pharmacology and pathophysiology of SGLT-2 inhibitors in patients with CKD, as well as their cardiovascular and renal effects in this population. We are focusing on the five agents that have been tested in cardiovascular outcome trials and that have been approved either in Europe or in North America: empagliflozin, dapagliflozin, canagliflozin, ertugliglozin, and sotagliflozin.
KW - Albuminuria
KW - Canagliflozin
KW - Cardiovascular events
KW - Chronic kidney disease
KW - Dapagliflozin
KW - Empagliflozin
KW - Ertugliflozin
KW - Progression
KW - Sodium-glucose co-transporter 2 inhibitors
KW - Sotagliflozin
UR - http://www.scopus.com/inward/record.url?scp=85147424818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147424818&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2022.108330
DO - 10.1016/j.pharmthera.2022.108330
M3 - Review article
C2 - 36513134
AN - SCOPUS:85147424818
SN - 0163-7258
VL - 242
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
M1 - 108330
ER -